TABLE 3

Antioxidant enzyme and aldose reductase mRNA levels with respect to 5′ALR2 genotype in patients with diabetic nephropathy

CATCuZnSODGPXMnSODALR2
Z − 2/X (n = 15)0.4 ± 0.04*0.3 ± 0.020.4 ± 0.03§0.8 ± 0.024.7 ± 0.8
Z + 2/Y (n = 3)0.6 ± 0.081.7 ± 0.470.6 ± 0.050.8 ± 02.0 ± 0.5
Z − 2/Z + 2 (n = 3)0.5 ± 0.051.3 ± 1.050.4 ± 00.6 ± 0.24.4 ± 3.6
X/Y (n = 5)0.6 ± 0.050.5 ± 0.070.7 ± 0.080.9 ± 0.023.4 ± 1.1
  • Data are mean fold increases ± SE of the PBMCs exposed to hyperglycemia versus those cultured under normal conditions. X, any allele other than Z + 2; Y, any allele other than Z − 2.

  • *

    * versus CAT X/Y, P = 0.02.

  • versus CuZnSOD Z + 2/Y, P < 0.001.

  • versus CuZnSOD Z − 2/Z + 2, P = 0.009.

  • §

    § versus GPX Z + 2/Y, P = 0.02.